We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+7.96%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$66.3M
AUM Growth
+$9.33M
Cap. Flow
+$8.28M
Cap. Flow %
12.49%
Top 10 Hldgs %
93.04%
Holding
21
New
4
Increased
2
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$9.61M
2
SMMT icon
Summit Therapeutics
SMMT
+$1.16M
3
NTRP
Neurotrope, Inc. Common
NTRP
+$860K
4
EVOK
Evoke Pharma
EVOK
+$498K
5
FOLD
Amicus Therapeutics
FOLD
+$316K

Top Sells

Rank Stock Value
1
ADXS
Advaxis Inc
ADXS
+$1.61M
2
TOVX icon
Theriva Biologics
TOVX
+$1.55M
3
AIXC
AIxCrypto Holdings Inc
AIXC
+$705K
4
NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
+$306K
5
ENLV icon
Enlivex Ltd
ENLV
+$214K

Sector Composition

Rank Sector Weight
1 Healthcare 97.53%
2 Technology 1.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRBP icon
1
Corbus Pharmaceuticals
CRBP
$170M
$30.8M 46.51%
124,631
+39,167
+46% +$9.61M
ABEO icon
2
Abeona Therapeutics
ABEO
$345M
$11.7M 17.7%
94,391
– –
NTBL
3
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$4.73M 7.14%
24,589
– –
AVXL icon
4
Anavex Life Sciences
AVXL
$222M
$4.16M 6.27%
724,205
– –
LUMO
5
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$2.25M 3.4%
10,393
– –
AMPE
6
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$2.19M 3.3%
9,128
– –
VNRX icon
7
VolitionRx Ltd
VNRX
$12M
$1.85M 2.8%
23,077
– –
ARCT icon
8
Arcturus Therapeutics
ARCT
$157M
$1.37M 2.07%
172,214
– –
SMMT icon
9
Summit Therapeutics
SMMT
$10.6B
$1.33M 2%
+100,000
New +$1.16M
KERX
10
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.23M 1.86%
200,000
– –
AIXC
11
AIxCrypto Holdings Inc
AIXC
$16.6M
$1.14M 1.72%
6
-2
-25% -$705K
NTRP
12
DELISTED
Neurotrope, Inc. Common
NTRP
$867K 1.31%
+45,388
New +$860K
ALDX icon
13
Aldeyra Therapeutics
ALDX
$91.7M
$620K 0.93%
124,096
-11,704
-9% -$60.3K
LSTA icon
14
Lisata Therapeutics
LSTA
$15.2M
$593K 0.89%
7,864
+4,159
+112% +$288K
EVOK
15
DELISTED
Evoke Pharma
EVOK
$543K 0.82%
+1,215
New +$498K
ADXSW
16
DELISTED
Advaxis Inc Warrants
ADXSW
$500K 0.75%
112,500
– –
FOLD
17
DELISTED
Amicus Therapeutics
FOLD
$357K 0.54%
+50,000
New +$316K
ENLV icon
18
Enlivex Ltd
ENLV
$70.7M
– –
-343
Closed -$214K
TOVX icon
19
Theriva Biologics
TOVX
$10.2M
– –
-233
Closed -$1.55M
NBSE
20
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-510
Closed -$306K
ADXS
21
DELISTED
Advaxis Inc
ADXS
– –
-15,000
Closed -$1.61M

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Knoll Capital Management held 21 positions worth $66.3M, up 16% from $57M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Knoll Capital Management deployed $8.28M of net new capital in Q1 2017, opening 4 new positions and adding to 2 existing holdings. Its largest new stake was Summit Therapeutics: 100,000 shares worth $1.33M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 95% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was AIxCrypto Holdings Inc, an estimated $705K trimmed.

  • Knoll Capital Management's largest Q1 2017 buy was Summit Therapeutics: 100,000 shares worth $1.33M.
  • Knoll Capital Management added most to Corbus Pharmaceuticals in Q1 2017, an estimated $9.61M increase.
  • Knoll Capital Management's biggest Q1 2017 reduction was AIxCrypto Holdings Inc, cutting an estimated $705K.
  • Knoll Capital Management fully exited Advaxis Inc in Q1 2017, selling an estimated $1.61M.
  • Knoll Capital Management's ten largest holdings make up 93% of its $66.3M portfolio in Q1 2017.
  • Knoll Capital Management opened 4 new positions and closed 4 in Q1 2017.
  • Knoll Capital Management's portfolio value rose 16% quarter-over-quarter to $66.3M.

Based on Knoll Capital Management's 13F filing for Q1 2017, filed 15 May 2017.